Table 2 Subgroup analysis of pooled HRs for OS in cancer patients with abnormally expressed CXCR7
From: Prognostic significance of CXCR7 in cancer patients: a meta-analysis
Subgroup analysis | No. of cohorts | Pooled HRs | Meta regression (p-value) | Heterogeneity | |
|---|---|---|---|---|---|
Random | I2 (%) | p-value | |||
Sample size | 0.122 | Â | Â | ||
 < 100 | 14 | 2. 04 [1.49–2.81] | – | 61.0 | 0.001 |
 ≥ 100 | 10 | 1.51 [1.3–1.66] | – | 0.0 | 0.798 |
Type of cancer | 0.379 | Â | Â | ||
 Digestive system carcinoma | 13 | 1.76 [1.45–2.14] | – | 8.5 | 0.361 |
 Non-digestive system carcinoma | 11 | 1.70 [1.38–2.10] | – | 56.7 | 0.010 |
Follow-up time | 0.689 | Â | Â | ||
 < 100 | 15 | 1.77 [1.49–2.11] | – | 36.9 | 0.075 |
 ≥ 100 | 9 | 1.67 [1.23–2.26] | – | 50.3 | 0.041 |
The region | 0.229 | Â | Â | ||
 Asia | 14 | 1.88 [1.54–2.28] | – | 44.0 | 0.039 |
 Other countries | 10 | 1.54 [1.20–1.98] | – | 38.9 | 0.099 |
NOS score | 0.604 | Â | Â | ||
 ≥ 7 | 18 | 1.69 [1.40–2.04] | – | 48.9 | 0.010 |
 < 7 | 6 | 1.86 [1.52–2.28] | – | 0.0 | 0.939 |
Source of HR | 0.074 | Â | Â | ||
 Directly | 13 | 1.52 [1.28–1.81] | – | 42.5 | 0.053 |
 Indirectly | 11 | 2.03 [1.67–2.47] | – | 0.0 | 0.640 |